Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First Human Dose Study of NNC6022-0001 in Healthy Adults
NCT06336005Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- Mar 2024
- Primary completion
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial in cardiometabolic disease comparing NNC6022-0001 with Placebo (2 arms). Primary endpoint: Number of treatment emergent adverse events. Started Mar 2024; status: completed.
02
Drugs
NNC6022-0001
03
Conditions
cardiometabolic disease
Beyond the preview
Go deeper on NCT06336005.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06336005.